Meissa Vaccines Logo Vertical.png
  • About

  • Team

  • Technology

  • Vaccine Pipeline

  • Careers

  • News

  • Contact

  • More

    Use tab to navigate through the menu items.
    • All Posts
    • Press Releases
    • In the News
    Search
    • Dec 16, 2021

    Meissa Appoints Drs. Dan H. Barouch and Mark J. Mulligan to Scientific Advisory Board

    • Oct 28, 2021

    Meissa Announces Positive Preliminary Clinical Data on Safety and Immunogenicity of Intranasal COVID

    • Aug 3, 2021

    Meissa Appoints Robert Walker, M.D., Chief Medical Officer

    • Jul 19, 2021

    Preclinical Data on Intranasal COVID-19 Vaccine Shows Protection from SARS-CoV-2 after Single Dose

    • Jun 30, 2021

    Meissa Vaccines Begins Study of RSV Vaccine Candidate in Seronegative Children

    • Apr 13, 2021

    Meissa Vaccines Appoints Dr. Michael Watson to Board of Directors

    • Mar 16, 2021

    Meissa Announces IND Clearance for Phase 1 Study of COVID-19 Intranasal Live Attenuated Vaccine

    • Jan 21, 2021

    Meissa Announces 1st Dosing in Phase 2 Study of Intranasal Live Attenuated Vaccine Candidate for RSV

    • Oct 14, 2020

    Meissa Vaccines Expands Leadership Team as Company Advances Intranasal RSV and COVID-19 Candidates

    • Jun 30, 2020

    Meissa Vaccines Provides a Pipeline Update on Vaccine Candidates for COVID-19 and RSV

    • Jan 10, 2020

    Meissa Vaccines Receives U.S. FDA Fast Track Designation for Respiratory Syncytial Virus Vaccine

    • Sep 26, 2019

    Meissa Vaccines Closes $30 Million Financing to Advance RSV Vaccine into Clinical Trials

    • Mar 27, 2019

    Meissa Vaccines Closes $3.4 Million Financing to Advance RSV Vaccine to Clinic

    • Aug 3, 2017

    Meissa Vaccines Announces Seed Round Investment from FundRx

    • Jul 12, 2017

    Meissa Vaccines Receives FDA Clearance of IND Application, Phase 1 Clinical Trial of MV-012-968

    • Jul 12, 2017

    Meissa Vaccines Awarded NIH SBIR Grant to Advance IND Preparations for RSV Vaccine Candidate

    • May 10, 2017

    Meissa Awarded NIH SBIR Grant to Support Development of Multivalent Human Rhinovirus Vaccine Candida

    Meissa Vaccines, Inc.

    info@meissavaccines.com

    • Twitter
    • LinkedIn

    © 2021 Meissa Vaccines, Inc.  

    Privacy Policy | Terms of Use